Previous 10 | Next 10 |
home / stock / nwphf / nwphf news
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding to marketed antipsychotics International TRS advisory committee will contribute to des...
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced t...
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients in the future A new definition of TRS patient responders indicated, which integrat...
Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures Results consistent with interim data from first 100 patients at this timepoint Detailed Study 014 results to be presented at the...
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia Newron Pharmaceuticals S.p....
2023-03-14 07:54:42 ET Newron Pharmaceuticals press release ( OTC:NWPHF ): FY GAAP EPS of -€0.98. Revenue of €6.09M (+5.7% Y/Y). For further details see: Newron Pharmaceuticals GAAP EPS of -€0.98, revenue of €6.09M
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced i...
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at one year; increase in magnitude of these measures over time Evenamide could be a potential breakthrough treatment in t...
Statistically significant, clinically meaningful improvements over baseline were seen across efficacy endpoints after six months; continued improvement was seen when compared with results after six weeks Newron plans to commence a pivotal study in treatment-resistant schizophrenia in 2023 ...
Newron Pharmaceuticals (NWPHF): FY GAAP EPS of -€1.18.Revenue of €5.26M (-25.3% Y/Y)Press Release For further details see: Newron Pharmaceuticals reports FY results
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients not...
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...